Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.39 |
| ▸ | CDK9 | P50750 | 4/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620392 | 0.87 | DDR1 (0.42) | DDR1 | |
| SCHEMBL13608142 | 0.86 | KDM1A (0.44) | DDR1MAOBHTR6BRD4ATAD2 | |
| SCHEMBL2269372 | 0.84 | BIRC2 (0.39) | CCNT1CDK9MAOBHTR6BRD4 | |
| SCHEMBL2269378 | 0.84 | BIRC2 (0.39) | CCNT1CDK9MAOBHTR6BRD4 | |
| SCHEMBL2274339 | 0.84 | BIRC2 (0.39) | CCNT1CDK9MAOBHTR6BRD4 | |
| SCHEMBL13608282 | 0.83 | BRD4 (0.42) | BRD4ATAD2BIRC2 | |
| SCHEMBL13608172 | 0.81 | BRD4 (0.41) | DDR1MAOBHTR6BRD4ATAD2 | |
| SCHEMBL13620505 | 0.80 | ADORA2A (0.41) | BIRC2 | |
| SCHEMBL13620507 | 0.79 | PIM1 (0.38) | CCNT1DDR1BRD4ATAD2 | |
| SCHEMBL13608342 | 0.79 | BIRC2 (0.40) | CCNT1CDK9MAOBHTR6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | CCNT1 1707/4885CDK9 355/4885DDR1 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.